{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05346354",
            "orgStudyIdInfo": {
                "id": "ALXN1210-NMO-317"
            },
            "organization": {
                "fullName": "Alexion Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD",
            "officialTitle": "A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 Antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "efficacy-and-safety-study-of-ravulizumab-iv-in-pediatric-participants-with-nmosd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-06-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-04-20",
            "studyFirstSubmitQcDate": "2022-04-20",
            "studyFirstPostDateStruct": {
                "date": "2022-04-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alexion Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD)."
        },
        "conditionsModule": {
            "conditions": [
                "Neuromyelitis Optica Spectrum Disorder"
            ],
            "keywords": [
                "Neuromyelitis Optica Spectrum Disorder",
                "Ravulizumab",
                "ALXN1210",
                "CNS Autoimmune Disorders",
                "NMO",
                "NMOSD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ravulizumab",
                    "type": "EXPERIMENTAL",
                    "description": "During the Primary Treatment Period, all participants will receive weight-based dosing of ravulizumab IV for a total of 50 weeks of treatment.\n\nDuring the Extension Period, participants will continue to receive weight-based dosing of ravulizumab IV for up to 104 weeks.",
                    "interventionNames": [
                        "Drug: Ravulizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ravulizumab",
                    "description": "Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight.\n\nDuring the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight.",
                    "armGroupLabels": [
                        "Ravulizumab"
                    ],
                    "otherNames": [
                        "ALXN1210",
                        "Ultomiris"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change From Baseline in the Annualized Relapse Rate at Week 50",
                    "timeFrame": "Baseline, Week 50"
                },
                {
                    "measure": "Time to First Adjudicated On-trial Relapse through Week 50",
                    "timeFrame": "Baseline through Week 50"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change From Baseline in Expanded Disability Status Scale Score At Week 50",
                    "description": "The score ranges are 0 to 10, higher score indicates worse outcome.",
                    "timeFrame": "Baseline, Week 50"
                },
                {
                    "measure": "Change From Baseline in Hauser Ambulation Index at Week 50",
                    "description": "The score ranges are 0 to 9, higher score indicates worse outcome.",
                    "timeFrame": "Baseline, Week 50"
                },
                {
                    "measure": "Change From Baseline in Visual Acuity at Week 50",
                    "timeFrame": "Baseline, Week 50"
                },
                {
                    "measure": "Change From Baseline in Confrontational Visual Fields at Week 50",
                    "timeFrame": "Baseline, Week 50"
                },
                {
                    "measure": "Change From Baseline in Color Vision at Week 50",
                    "timeFrame": "Baseline, Week 50"
                },
                {
                    "measure": "Serum Ravulizumab Concentration",
                    "timeFrame": "Predose and postdose (at end of infusion) on Day 1, Weeks 2, 10, 18, 26, and 42, and predose on Week 50"
                },
                {
                    "measure": "Change from Baseline in Free Serum Complement Component 5 (C5) Concentration Over Time Through Week 50",
                    "timeFrame": "Baseline through Week 50"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must be anti-AQP4 Ab-positive and have a diagnosis of NMOSD as defined by the 2015 international consensus diagnostic criteria.\n* Complement inhibitor treatment-na\u00efve participants must have had at least 1 attack or relapse in the last 12 months prior to the Screening Period.\n* Expanded Disability Status Scale (EDSS) score \u2264 7.\n* Eculizumab-experienced participants must be clinically stable per Investigator for 30 days and have been treated with eculizumab in Study ECU-NMO-303 for at least 90 days prior to screening with no missed doses within 2 months prior to Day 1.\n* Participants who enter the study receiving supportive IST(s) (eg, corticosteroid, azathioprine \\[AZA\\], mycophenolate mofetil \\[MMF\\], methotrexate \\[MTX\\], tacrolimus \\[TAC\\], cyclosporin \\[CsA\\], or cyclophosphamide \\[CYC\\]) for the prevention of relapse, either in combination or monotherapy, must be on a stable dosing regimen of adequate duration prior to Screening and remain on a stable dosing regimen during the Screening Period.\n* To reduce the risk of meningococcal infection (Neisseria meningitidis), all participants must be vaccinated against meningococcal infection.\n* Documented vaccination for Hib and S pneumoniae at least 14 days prior to Day 1 according to national/local guidelines for the applicable age group.\n\nExclusion Criteria:\n\n* Use of rituximab within 6 months prior to Day 1.\n* Currently treated with a biologic medications (other than eculizumab) that may affect immune system functioning, or has stopped treatment with a biologic medication that may affect immune system functioning, and 5 half lives of the medication have not elapsed by the time of the Screening Visit.\n* Use of intravenous immunoglobulin (IVIg) or plasma exchange (PE) within 3 weeks prior to Screening.\n* Participation in another investigational drug or investigational device study (other than Study ECU-NMO-303) within 5 half lives of that investigational product (if known) or 30 days before initiation of the first dose of study drug, whichever is longer.\n* Use of immunomodulatory therapies for multiple sclerosis within 3 months prior to Screening.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alexion Pharmaceuticals, Inc. (Sponsor)",
                    "role": "CONTACT",
                    "phone": "1-855-752-2356",
                    "email": "clinicaltrials@alexion.com"
                }
            ],
            "locations": [
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27705",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Edmonton",
                    "state": "Alberta",
                    "zip": "T6G 1C9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 53.55014,
                        "lon": -113.46871
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 1X8",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H3T1C5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Le Kremlin-Bic\u00eatre",
                    "zip": "94270",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.81471,
                        "lon": 2.36073
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Marseille",
                    "zip": "13005",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.29551,
                        "lon": 5.38958
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Montpellier Cedex 5",
                    "zip": "34295",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.61092,
                        "lon": 3.87723
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Bochum",
                    "zip": "44791",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.48165,
                        "lon": 7.21648
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Giessen",
                    "zip": "35392",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.58727,
                        "lon": 8.67554
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Catania",
                    "zip": "95123",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 37.49223,
                        "lon": 15.07041
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Chieti",
                    "zip": "66013",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 42.34827,
                        "lon": 14.16494
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Gallarate",
                    "zip": "21013",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.66019,
                        "lon": 8.79164
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Roma",
                    "zip": "00165",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Yokohama-shi",
                    "zip": "232-0024",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.43333,
                        "lon": 139.65
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Goyang-si",
                    "zip": "10408",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.65639,
                        "lon": 126.835
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Esplugues de Llobregat",
                    "zip": "8950",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.37732,
                        "lon": 2.08809
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009471",
                    "term": "Neuromyelitis Optica"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009188",
                    "term": "Myelitis, Transverse"
                },
                {
                    "id": "D000020278",
                    "term": "Demyelinating Autoimmune Diseases, CNS"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009902",
                    "term": "Optic Neuritis"
                },
                {
                    "id": "D000009901",
                    "term": "Optic Nerve Diseases"
                },
                {
                    "id": "D000003389",
                    "term": "Cranial Nerve Diseases"
                },
                {
                    "id": "D000003711",
                    "term": "Demyelinating Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12414",
                    "name": "Neuromyelitis Optica",
                    "asFound": "Neuromyelitis Optica",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12142",
                    "name": "Myelitis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12143",
                    "name": "Myelitis, Transverse",
                    "relevance": "LOW"
                },
                {
                    "id": "M22098",
                    "name": "Demyelinating Autoimmune Diseases, CNS",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M12387",
                    "name": "Neuritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12833",
                    "name": "Optic Neuritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12832",
                    "name": "Optic Nerve Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6605",
                    "name": "Cranial Nerve Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6909",
                    "name": "Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4103",
                    "name": "Neuromyelitis Optica Spectrum Disorder",
                    "asFound": "Neuromyelitis Optica Spectrum Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3988",
                    "name": "Myelitis",
                    "relevance": "LOW"
                },
                {
                    "id": "T4263",
                    "name": "Optic Neuritis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000629409",
                    "term": "Ravulizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000051056",
                    "term": "Complement Inactivating Agents"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M287455",
                    "name": "Ravulizumab",
                    "asFound": "CCT",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6392",
                    "name": "Complement System Proteins",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}